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Abstract
Background: Chronic hepatitis B virus(HBV) infection is a major cause of liver related morbidity and mortality. HBV
infection remains largely underdiagnosed in Asian American population, and it is also poorly linked to clinical care.
We, therefore, assessed the HBV prevalence and evaluated linkage to care among Korean Americans in order to
develop strategic plans to reduce the impact of HBV in a high risk community.
Methods: Serologic screening and survey were provided to 7157 Korean American adults (age 21–100) in New
Jersey between December 2009 and June 2015. All participants were tested for hepatitis B surface antigen (HBsAg),
hepatitis B surface antibody (anti-HBs), and hepatitis B core IgG antibody (anti-HBc). Additional survey was
conducted on the subjects chronically infected with HBV on their history of infection. Self-administered
questionnaires were employed to evaluate demographic and epidemiologic characteristics.
Results: Of those 7157screened, 171 (2.4 %) were HBV infected, 2736(38.2 %) were susceptible to HBV, and 4250(59.
4 %) were immune. The prevalence of chronic HBV varied between the age groups: 1.18 % (age21-30); 2.53 % (age
31–40); 2.76 % (age 41–50); 2.90 % (age 51–60); 2.06 % (age 61–70); and 1.37 % (age 71–100). The rate of HBsAg
was significantly higher in males (3.04 %) as compared to females (1.93 %). At least 75 % of these HBV infected
subjects had been previously diagnosed, but were not engaged in care.
Conclusion: This screening study suggests that the HBV prevalence in Korean Americans is significantly lower than
currently understood. On the other hand, many of the individuals chronically infected with HBV cannot access care,
suggesting a poor linkage-to-care (LTC). Further, a large percentage of the population is still susceptible to HBV.
Study findings will be used to develop strategies to tailor community-based HBV screenings and LTC to the high
risk populations.
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Background
Chronic hepatitis B (CHB) is a serious global health issue
affecting more than 240 million people. Approximately
25 % or more of these CHB patients may eventually suffer
from liver cirrhosis, primary liver cancer or other complica-
tions of CHB [1–4]. There are three major issues re-
garding CHB today. First, numerous people have not
been screened and thus are not aware of the fact that
they are infected [5, 6]. Second, despite the availability
of vaccine since early 1980s, many are still at risk and
require vaccination [6, 7]. Third, even with the avail-
ability of effective antiviral treatment for CHB, a major-
ity of the CHB treatment candidates are not linked to
adequate care [8–11].
There is a marked disparity between different racial and
ethnic groups in the prevalence of CHB and its complica-
tions. For instance, 5–10 % of all Asian Americans have
HBV infection as compared with 0.2 % of Caucasian
Americans [3, 5]. In the United States alone, an estimated
two million people are chronically infected with HBV.
Nearly 70 % of these HBV infected individuals are un-
aware they have the virus. Furthermore, less than 10% of
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patients who may need treatment in the United States are
currently receiving antiviral medication. Thus, hepatitis B
is not only significantly underdiagnosed, but it is also
undertreated [6, 7].
The fact that the majority of the people chronically in-
fected with HBV are not aware of their infection clearly
demonstrates that there are barriers to screening in the
United States. The barriers to screening are multi-factorial.
Patient-related obstacles are mostly consisted of lack of
awareness about the disease, language and cultural barriers,
and financial issues [8, 12]. Additionally, providers and
healthcare system currently available in the US lack the
understanding of the significance of CHB. To be specific,
there is a lack of public health systems to meet the needs
of multicultural populations [9, 13]. There is also a poor
communication between providers and patients of different
racial, ethnic, or cultural backgrounds. Last but not least,
there is a significant lack of cross-cultural training in health
professionals [11, 14, 15]. As a result, there is a serious lack
of adequate health access models available for minority
populations.
New Jersey and its vicinity are heavily concentrated
with Asian Americans, many of whom are currently
infected with HBV. Despite a rapidly growing population
of Korean Americans in New Jersey, a majority of these
people have not been accessed by the currently available
HBV screening program. During the period between
December 2009 and June 2015, Center for Viral Hepa-
titis (CVH) and Asian Liver Center (ALC) of Holy Name
Medical Center carried out a total of 128 community
outreach HBV screening events in Central and Northern
New Jersey. Serologic screening and survey were pro-
vided to a total of 7199 Korean American adults (mean
age 52) throughout these events. All the participants
were tested for hepatitis B surface antigen (HBsAg),
hepatitis B surface antibody (anti-HBs), and hepatitis B
core IgG antibody (anti-HBc).
This study and the results of other recent studies clearly
suggest that the reported prevalence of hepatitis B among
Koreans in both Korea and the United States may be
higher than the true prevalence [16, 17]. The results of the
current study also indicate an urgent need to improve vac-




A large scale community-based Hepatitis B Screening
and Awareness Campaign was led by CVH and ALC of
Holy Name Medical Center in the state of New Jersey.
CVH and ALC are two major non-profit organizations
devoted to promoting CHB screening and linkage to
care in Asian American community. All our staff were
consisted of community physicians with expertise in the
field of CHB, nurses, and community volunteers. CVH
and ALC have collaborative relationship with local hos-
pitals, community organizations and physicians to work
cooperatively in a multidisciplinary manner to ensure
the highest quality of care for screening, education, vac-
cination, and linkage to care for the individuals chronic-
ally infected with HBV.
Our hepatitis B campaign consisted of a total of 128
community outreach screenings and education seminars
at various locations throughout Central and Northern
New Jersey during the period between December 2009
and June 2015. CVH and ALC organized and hosted all
the campaign events. A total of 7199 Korean American
immigrants were screened for hepatitis B in 98 churches,
12 community centers, and 18 health fairs in five different
counties of New Jersey. All the HBV infected subjects
were referred to specialists within the community, and
those who were not immune to HBV were vaccinated.
Participant characteristics
All the participants were Korean Americans currently res-
iding in New Jersey. 99.5 % of the participants were born
in Korea. Their ages ranged from 21 to 100, with a mean
age of 52. A vast majority (>85 %) of the participants were
reported to having lived in the United States for a mini-
mum of 10 years. More than 99 % of the participants pre-
ferred Korean as the language for communication.
Serological screening and survey
Hepatitis B Screening included the three following tests:
HBsAg, anti-HBs, and anti-HBc (IgG). The blood draw-
ing and processing were conducted by phlebotomists or
registered nurses, and all the results were reviewed by
physicians. All the participants who had screening tests
were contacted by the following means of communica-
tion: telephone and mail. The participants who did not
respond, for instance, were tracked down and were per-
sistently contacted through the means of telephone calls
and certified mails.
Self-administered questionnaires were employed to
evaluate demographic and epidemiologic characteristics.
At the time of the screening, participants completed a
survey written in both English and Korean. The items in
the survey included gender, date of birth, country of
birth, years in the United States, and preferred language
of communication. All participants provided written
informed consent. Some of the screening events also
included Hepatitis B awareness seminars and question
and answer sessions to address numerous questions the
participants had.
Data analysis
Exact binomial 95 % confidence intervals (CIs) were
calculated for prevalence of HBsAg seropositivity. A 2-
Hyun et al. BMC Infectious Diseases  (2016) 16:415 Page 2 of 7




We conducted a total of 128 screening events in Central
and Northern New Jersey between December 2009 and
June 2015. Figure 1 shows the age and gender distribution
of 7095 participants. Of 7199 screened, 104 were unspeci-
fied. The average age was 52 years, and 58.3 % were
females. Approximately half of the participants belonged
to the age group of 41–60.
Serological data
Of 7199 Korean Americans screened, the results for
7157 participants were available. Of 7157 participants,
171 (2.4 %) were HBV infected, 4250 (59.4 %) were
immune, and 2736 (38.2 %) were susceptible to HBV
(Fig. 2). Of 4250 (59.4 %) immune subjects, 2319
(32.7 %) were recovered from past infection, and 1931
(26.7 %) were vaccinated.
The prevalence of HBV varied significantly between age
groups: 1.18 % (age21-30); 2.53 % (age 31–40); 2.76 % (age
41–50); 2.90 % (age 51–60); 2.06 % (age 61–70); and
1.37 % (age 71–100). The highest HBsAg positive rates are
found in the group between age 41 and 60. To deter-
mine a statistical difference between age groups, we
compared the HBV prevalence in the youngest age
group (age 21–30) with older age groups. The HBV
prevalence in the age group of 21–30 years was signifi-
cantly different only from two other age groups (age
41–50 and age 51–60) with the p-values of 0.0436 and
0.028, respectively (Table 1).
Of 171 HBV infected subjects, all but three were born
in Korea. There were 88 males, 81 females, and 2
unknown. As shown in Fig. 3, the rate of HBsAg is signifi-
cantly higher in males (3.04 %) as compared to females
(1.93 %) (p = 0.003).
Infection history of the HBsAg-positive subjects
A survey was carried out to determine how many of
these HBsAg-positive subjects might have known their
infection status prior to the current screening (Fig. 4). It
showed that out of 171 HBV infected subjects, 128 knew
that they were chronically infected prior to the screen-
ing, 33 just learned that they were infected, and the
remaining 10 were not sure of their hepatitis B status.
Of those 128 previously diagnosed subjects, at least 105
have reported of having immigrated to the United States
before 2000. About 10 % of these HBV infected subjects
have seen physicians for hepatitis B, but none of them
engaged in any further work up. A vast majority (>95 %)
of these subjects had no symptoms or were not aware of
potential complications of hepatitis B such as cirrhosis
and liver cancer.
Acquisition of immunity
Of 7157 participants screened, a total of 4250 were im-
mune, showing 59.4 % immune rate (Fig. 2). We looked
into acquisition of immunity from vaccination versus
past infection. Of 4250 immune participants, 1931 par-
ticipants developed immunity from vaccination, and the
remaining 2319 participants developed immunity from
past infection. The ratio of the acquisition of immunity
from vaccination to the acquisition of immunity from
past infection varied in different age groups. As shown
in Fig. 5, the majority of immunity came from
21-30 31-40 41-50 51-60 61-70 71-100
Female 304 486 938 1360 796 314











Fig. 1 Distribution of the study sample by age and gender
Fig. 2 Hepatitis B status in a Korean American population in
New Jersey









95 % CI (%)
21 - 30 508 6 1.18 0.43-2.55
31 - 40 910 23 2.53 1.61-3.77
41 - 50 1559 43 2.76 2.00-3.70
51 - 60 2175 63 2.90 2.23-3.69
61 - 70 1359 28 2.06 1.37-2.96
71 - 100 584 8 1.37 0.59-2.68
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vaccination in younger age groups (age 21–40) while the
majority of immunity came from previous infection in
older age groups (51–100).
Lack of immunity in all age groups
Despite the availability of vaccine for over three decades,
there were still many subjects who were not immune to
HBV. Of 7157 screened in this study, 2736 participants
(38.2 %) lacked protective antibody to HBV (Fig. 2). This
lack of immunity was apparent in all age groups (Fig. 5).
Discussion
In the current study of our community-based hepatitis B
screening campaign, we performed an epidemiologic
evaluation on hepatitis B in Korean Americans. On a
total of 7157 participants screened between December
2009 and June 2015 from New Jersey, this study shows
that the prevalence of CHB in Korean American adults
is 2.4 %, which is significantly lower than currently
understood [16, 17]. Surprisingly, a majority of the HBV
infected subjects (80.7 %) had not been linked to
adequate care for monitoring and treatment. In addition,
we found 59.4 % as immune and 38.2 % as susceptible to
HBV infection.
One noteworthy aspect of this study is the demonstration
of a HBV prevalence of 2.4 % among Korean American
immigrants, which is substantially lower than currently
believed. The prevalence of chronic hepatitis B infection for
Koreans in South Korea has been also reported to be as
high as 8 % until recent years [16, 17]. In a review of the
studies on the Korean American population, we find a
trend of decreasing prevalence rates of hepatitis B over the
past three decades. A community-based Hepatitis B screen-
ing campaign by Hann et al. have evaluated 6130 Korean
Americans in eastern United States between 1988 and 1990
and showed a HBsAg positive rate of 6.1 %, with 8 % for
males and 4.4 % for females [18]. Another community-
based study on 609 Korean Americans in Colorado be-
tween 2004 and 2007 revealed a HBV prevalence of 4 %
[19]. It also revealed 55 % immune and 41 % susceptible to
infection. More recently, a study on 973 Korean American
residents from California, which took place between 2009
and 2010, demonstrated a 3.0 % HBV prevalence rate [20].
In this study, the immune rate was higher at 76 %, and only
20 % were susceptible to infection.
The relatively low HBV prevalence found in the current
study is congruent with the results of the recent studies
from Korea. In an evaluation of 50,140 Korean partici-
pants for HBsAg positivity over a period of 12 years be-
tween 1998 and 2010, investigators found a decreasing
rate of HBsAg positivity: 4.61 % in 1998; 3.69 % in 2005,
and 2.98 % in 2010 [21]. They also showed that the per-
centage of HBV infected individuals in the age group of
10–20 years decreased from 2.2 % in 1998 to 0.12 % in
2010. In addition, the percentage of the HBV infected in
the age group 10–39 years decreased from 4.72 % in 1998
to 2.29 % in 2010. According to these studies, South Korea
may belong to low intermediate endemic (2-4 %) area as
recently reported by CDC Health Information for Inter-
national Travel 2016 [22].
The decreasing HBV prevalence in Koreans in the
United States and Korea may be largely attributed to HBV
immunization programs and other preventive strategies
[23]. Korean national Immunization Program for all neo-
nates began in 1995 to include universal vaccination, re-
gardless of maternal HBsAg status, which helped to
prevent both vertical and horizontal transmission [23, 24].
Likewise, universal vaccination programs have contributed
to the marked decline in HBV prevalence rate in people
younger than 20 years of age worldwide [18, 23]. A similar
decline in HBV prevalence was reported in Taiwan follow-
ing its neonatal vaccination program [25]. These are con-
gruent with results of the current study, which show an
increased vaccination rate and a decreased HBV preva-
lence in younger population.
There are important limitations to consider in this
study. First, the participants, namely Korean American



























Fig. 4 History of HBV infection in the HBsAg-positive subjects
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overall Korean population in the United States. Education
level and socioeconomic status, for instance, are import-
ant factors known to affect HBV prevalence [26, 27]. How
these factors might have influenced the results of the
current study are unknown. Secondly, the age distribution
in our study population may not represent the entire
population. For instance, our study sample under-
represents younger age groups relative to the older age
groups. Youngest age group below 20, who are known to
have a very low HBV prevalence, for instance, are not rep-
resented in our study population. Thirdly, it is difficult to
determine how the screening rates would have affected
the prevalence. For instance, many of our study subjects
underwent screening knowing their hepatitis B status. If a
greater number of HBV infected subjects in proportion to
non-infected subjects underwent the screening in this
campaign, the HBV prevalence would have been overesti-
mated. Finally, differences in the settings for screening
could have affected the prevalence. It should be noted,
however, that the non-clinical community settings for
screening employed in this study were similar to the
community settings for screening employed in previous
studies which had demonstrated significantly higher HBV
prevalence [18, 19].
Although the HBV prevalence is significantly declined,
the percentage of the Korean American population sus-
ceptible to HBV infection remains high. More than one
third of the participants were susceptible, and this lack
of immunity was evident throughout all the age groups
(Fig. 5). It is also remarkable to note that a substantial
percentage of a younger age group (age 21–30) still
remains susceptible to HBV infection. In this age group,
approximately 3.1 % had hepatitis B infection previously,
and 59.3 % had detectable anti-HBs level as result of
vaccination. Since 5-10 % of the persons vaccinated
against hepatitis B may not respond [28], we can
estimate that approximately one third of the subjects in
this age group are not vaccinated.
Another noteworthy aspect of this study is the demon-
stration that a majority of the HBV infected subjects
found in the current campaign had been previously diag-
nosed (Fig. 4). These individuals chronically infected
with HBV are not engaged in any care, reflecting a poor
hepatitis B LTC in Korean American community. Other
investigators have also reported that only a minority of
HBV infected people can access care [9-11]. In fact, it
was estimated that only 40 % of the HBV infected sub-
jects screened in community setting were successfully
linked to care [10, 11]. These challenges met in LTC are
most often related to finding qualified providers within
the community, who can provide care in a linguistically
and culturally sensitive manner. Improvements in pa-
tient education, counseling, and navigation efforts may
also be an effective strategy to improve linkages from
community-based testing sites to HBV-directed medical
care. Because routine and ongoing monitoring is the
foundation for an effective HBV medical management,
future efforts to improve outcomes among HBV infected
people should provide a greater emphasis on LTC.
This study illustrates how Community-based screening
can provide an effective screening for CHB in ethnic
minority populations, where language, culture, and
financial barriers may preclude them to access appropriate
care. There are more than several ways community-based
health initiatives can be achieved, depending upon who
initiates, drives and carries out these initiatives and the de-
gree of their input [29, 30]. In the current community-
based campaign for hepatitis B, individual leaderships and
community organizations carried out the entire project
with an external fiscal support. We offered comprehensive
services including screening programs, educational out-
reach, vaccination, and a link to community physicians
21-30 31-40 41-50 51-60 61-70 71-100
Recovered 3.1% 14.5% 29.2% 40.7% 42.2% 44.0%
Vaccinated 59.3% 48.8% 29.2% 20.6% 16.3% 10.3%









Fig. 5 Acquisition of immunity in all age groups. The percentage values represent percent of participants in each age group
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with expertise in hepatitis B care. Of note, our campaign
also included education seminars and forums for physi-
cians who had greatest contacts with the Asian American
community. In addition to updating physicians on the
effective HBV prevention, antiviral treatments and moni-
toring, these educational activities helped motivate pro-
viders to get involved in community outreach. Secondly,
we fostered strategic partnerships with key community
organizations which promoted community ownership and
sustained engagement of the campaign. As a result, a total
of 160 subjects chronically infected with HBV identified in
this campaign were referred to specialists for confirmatory
testing, monitoring, and antiviral treatments. Among
these HBV infected subjects referred to specialists, 76 %
had initial consultations within a 6 month period.
Conclusion
The current study on one of the largest HBV screening
campaigns among Korean Americans demonstrates a
significantly decreased HBV prevalence of 2.4 %. The
study also reveals a poor LTC for those HBV infected
subjects, who require monitoring and/or medical treat-
ments. A comprehensive, community-based screening
and evaluation program described in this report may be
effectively implemented in other ethnic populations to
facilitate hepatitis B care.
Abbreviations
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